POMP

Summary

POMP (proteasome maturation protein, HGNC:20330) is a protein-coding gene on chromosome 13q12.3, encoding Proteasome maturation protein (Q9Y244). Molecular chaperone essential for the assembly of standard proteasomes and immunoproteasomes.

The protein encoded by this gene is a molecular chaperone that binds 20S preproteasome components and is essential for 20S proteasome formation. The 20S proteasome is the proteolytically active component of the 26S proteasome complex. The encoded protein is degraded before the maturation of the 20S proteasome is complete. A variant in the 5’ UTR of this gene has been associated with KLICK syndrome, a rare skin disorder.

Source: NCBI Gene 51371 — RefSeq curated summary.

At a glance

• Gene–disease (curated): keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 158 total — 4 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_015932

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20330
Approved symbol	POMP
Name	proteasome maturation protein
Location	13q12.3
Locus type	gene with protein product
Status	Approved
Aliases	HSPC014, UMP1
Ensembl gene	ENSG00000132963
Ensembl biotype	protein_coding
OMIM	613386
Entrez	51371

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 13 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000380842, ENST00000460403, ENST00000697661, ENST00000697662, ENST00000697663, ENST00000697716, ENST00000697717, ENST00000697718, ENST00000697719, ENST00000697720, ENST00000697721, ENST00000697722, ENST00000883661, ENST00000883662, ENST00000928922

RefSeq mRNA: 1 — MANE Select: NM_015932 NM_015932

CCDS: CCDS9331

Canonical transcript exons

ENST00000380842 — 6 exons

Exon	Start	End
ENSE00003577317	28662410	28662507
ENSE00003676638	28672339	28672432
ENSE00003971501	28678035	28678959
ENSE00003971504	28664509	28664569
ENSE00003971506	28659130	28659187
ENSE00003971510	28668473	28668574

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 99.43.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 137.7309 / max 3368.2890, expressed in 1826 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134581	137.7309	1826

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart right ventricle	UBERON:0002080	99.43	gold quality
biceps brachii	UBERON:0001507	98.94	gold quality
mucosa of sigmoid colon	UBERON:0004993	98.90	gold quality
corpus epididymis	UBERON:0004359	98.86	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.76	gold quality
colonic mucosa	UBERON:0000317	98.72	gold quality
oral cavity	UBERON:0000167	98.68	gold quality
adult organism	UBERON:0007023	98.67	gold quality
male germ cell	CL:0000015	98.63	gold quality
sperm	CL:0000019	98.60	gold quality
upper leg skin	UBERON:0004262	98.57	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.57	gold quality
tendon of biceps brachii	UBERON:0008188	98.57	gold quality
cauda epididymis	UBERON:0004360	98.56	gold quality
diaphragm	UBERON:0001103	98.54	gold quality
skin of hip	UBERON:0001554	98.53	gold quality
trabecular bone tissue	UBERON:0002483	98.48	gold quality
decidua	UBERON:0002450	98.47	gold quality
medial globus pallidus	UBERON:0002477	98.45	gold quality
triceps brachii	UBERON:0001509	98.41	gold quality
superficial temporal artery	UBERON:0001614	98.41	gold quality
caput epididymis	UBERON:0004358	98.37	gold quality
pigmented layer of retina	UBERON:0001782	98.35	gold quality
substantia nigra pars compacta	UBERON:0001965	98.31	gold quality
gluteal muscle	UBERON:0002000	98.29	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.27	gold quality
body of tongue	UBERON:0011876	98.27	gold quality
globus pallidus	UBERON:0001875	98.24	gold quality
pericardium	UBERON:0002407	98.24	gold quality
type B pancreatic cell	CL:0000169	98.19	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	126.97
E-CURD-46	yes	20.16
E-MTAB-5061	yes	5.87
E-MTAB-6819	no	1714.58
E-MTAB-8271	no	1408.89
E-MTAB-8559	no	1338.29
E-MTAB-10596	no	1205.78
E-MTAB-7052	no	623.79
E-MTAB-6911	no	556.36
E-HCAD-30	no	243.58
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting POMP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-3659	99.70	67.97	694
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-561-3P	99.64	70.90	3647

Literature-anchored findings (GeneRIF, showing 13)

• POMP/proteassemblin/hUmp1 may be tetramerised and is localized to the cytoplasm and the nucleus (PMID:16624403)
• Data show that POMP facilitates the main steps in 20S core complex formation at the ER to coordinate the assembly process and to provide cells with freshly formed proteasomes at their site of function. (PMID:17948026)
• A single-nucleotide deletion in the POMP 5’ UTR causes a transcriptional switch and altered epidermal proteasome distribution in KLICK genodermatosis. (PMID:20226437)
• KLICK is caused by reduced levels of POMP, leading to proteasome insufficiency in differentiating keratinocytes (PMID:22235297)
• Single-nucleotide polymorphisms in POMP gene is associated with breast cancer risk after menopausal hormone replacement therapy. (PMID:24080446)
• microRNA-101 (miR-101) targets the proteasome maturation protein POMP, leading to impaired proteasome assembly and activity, and resulting in accumulation of p53 and cyclin-dependent kinase inhibitors, cell cycle arrest, and apoptosis. (PMID:26145175)
• studies validate a role for the NRF2/POMP axis in bortezomib resistance and identify NRF2 and POMP as potentially attractive targets for chemosensitization to this proteasome inhibitor (PMID:26483548)
• MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child (PMID:26615982)
• POMP is overexpressed and participates in the increase of proteasome assembly and activity in psoriatic skin. (PMID:28728908)
• POMP-related autoinflammation and immune dysregulation disease (PRAID) discovered in two unrelated individuals with a unique constellation of early-onset combined immunodeficiency, inflammatory neutrophilic dermatosis, and autoimmunity, is reported. (PMID:29805043)
• The A alleles of SEMA6A and POMP genes are likely the risk factors of disease development in Georgians. (PMID:31687947)
• NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. (PMID:32123008)
• KLICK Syndrome Linked to a POMP Mutation Has Features Suggestive of an Autoinflammatory Keratinization Disease. (PMID:32425927)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	pomp	ENSDARG00000032296
mus_musculus	Pomp	ENSMUSG00000029649
rattus_norvegicus	Pomp	ENSRNOG00000049229
drosophila_melanogaster	Pomp	FBGN0032884

Protein

Protein identifiers

Proteasome maturation protein — Q9Y244 (reviewed: Q9Y244)

Alternative names: Proteassemblin, Protein UMP1 homolog, Voltage-gated K channel beta subunit 4.1

All UniProt accessions (4): A0A1W2PS02, A0A8V8TLM3, A0A8V8TMM8, Q9Y244

UniProt curated annotations — full annotation on UniProt →

Function. Molecular chaperone essential for the assembly of standard proteasomes and immunoproteasomes. Degraded after completion of proteasome maturation. Mediates the association of 20S preproteasome with the endoplasmic reticulum.

Subunit / interactions. Constituent of preproteasomes, but not of mature 20S proteasomes. Within the preproteasome, may directly interact with PSMB1/beta6, PSMB4/beta7, PSMB5/beta5, PSMB6/beta1 and PSMB9/beta1i. Interaction with PSMB8/beta5i has been observed in PubMed:10973495, but not in PubMed:10926487. Forms tetramers.

Subcellular location. Cytoplasm. Cytosol. Nucleus. Microsome membrane.

Tissue specificity. Strongly expressed from the basal layer to the granular layer of healthy epidermis, whereas in KLICK patients there is a gradual decrease of expression toward the granular layer.

Disease relevance. Keratosis linearis with ichthyosis congenita and sclerosing keratoderma (KLICK) [MIM:601952] A keratinizing disorder characterized by ichthyosis, palmoplantar keratoderma with constricting bands around fingers, flexural deformities of fingers and keratotic papules in a linear distribution on the flexural side of large joints. Histological examination of the skin of affected individuals shows hypertrophy and hyperplasia of the spinous, granular and horny epidermal layer. The disease is caused by variants affecting the gene represented in this entry. Proteasome-associated autoinflammatory syndrome 2 (PRAAS2) [MIM:618048] An autosomal dominant autoinflammatory disorder characterized by onset in early infancy and severe inflammatory neutrophilic dermatitis, autoimmunity, and variable immunodeficiency. The disease is caused by variants affecting the gene represented in this entry.

Induction. By IFNG/IFN-gamma.

Similarity. Belongs to the POMP/UMP1 family.

RefSeq proteins (1): NP_057016* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008012	Ump1	Family

Pfam: PF05348

UniProt features (15 total): helix 7, strand 3, turn 2, chain 1, short sequence motif 1, cross-link 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
8QYL	ELECTRON MICROSCOPY	2.67
8QYJ	ELECTRON MICROSCOPY	2.73
8QYM	ELECTRON MICROSCOPY	2.73
8TM6	ELECTRON MICROSCOPY	2.8
8QYN	ELECTRON MICROSCOPY	2.88
8YIX	ELECTRON MICROSCOPY	2.91
8QZ9	ELECTRON MICROSCOPY	2.95
8TM4	ELECTRON MICROSCOPY	3
8TM5	ELECTRON MICROSCOPY	3
8YIY	ELECTRON MICROSCOPY	3.41
8QYS	ELECTRON MICROSCOPY	3.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y244-F1	81.76	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 39

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9907900	Proteasome assembly

MSigDB gene sets: 282 (showing top): KEGG_PROTEASOME, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_PROTEASOME_ASSEMBLY, ONKEN_UVEAL_MELANOMA_UP, GGAANCGGAANY_UNKNOWN, GNF2_XRCC5, ELK1_01, P300_01, NRF2_01, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, GRADE_COLON_AND_RECTAL_CANCER_UP, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY

GO Biological Process (1): proteasome assembly (GO:0043248)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), nuclear speck (GO:0016607), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular membrane-bounded organelle	2
cytoplasm	2
protein-containing complex assembly	1
binding	1
intracellular anatomical structure	1
nuclear ribonucleoprotein granule	1
endomembrane system	1

Protein interactions and networks

STRING

1298 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
POMP	PSMB8	P28062	901
POMP	PSMA3	P25788	882
POMP	PSMB9	P28065	876
POMP	PSMB1	P20618	869
POMP	PSMA1	P25786	867
POMP	PSMA4	P25789	861
POMP	PSMG1	O95456	849
POMP	PSMG3	Q9BT73	788
POMP	PSMG4	Q5JS54	787
POMP	PSMA7	O14818	766
POMP	ECPAS	Q5VYK3	726
POMP	PSME4	Q14997	722
POMP	PSMB4	P28070	718
POMP	PSMG2	Q969U7	717
POMP	PSMB5	P28074	710

IntAct

141 interactions, top by confidence:

A	B	Type	Score
PSMA1	PSMA7	psi-mi:“MI:0914”(association)	0.950
PSMA1	PSMA7	psi-mi:“MI:2364”(proximity)	0.950
PSMA7	PSMA1	psi-mi:“MI:0914”(association)	0.950
POMP	PSMB7	psi-mi:“MI:0915”(physical association)	0.910
PSMB7	POMP	psi-mi:“MI:0915”(physical association)	0.910
POMP	PSMB3	psi-mi:“MI:0915”(physical association)	0.860
POMP	PSMB1	psi-mi:“MI:0915”(physical association)	0.860
PSMB3	POMP	psi-mi:“MI:0915”(physical association)	0.860
PSMA2	PSMA7	psi-mi:“MI:0914”(association)	0.850
PSMG2	PSMG1	psi-mi:“MI:0914”(association)	0.850
PSMA6	PSMA7	psi-mi:“MI:0914”(association)	0.850
POMP	PSMB2	psi-mi:“MI:0915”(physical association)	0.810
PSMA5	PSMA7	psi-mi:“MI:0914”(association)	0.800
PSMB7	PSMA7	psi-mi:“MI:0914”(association)	0.790
PSMB2	PSMA7	psi-mi:“MI:0914”(association)	0.790
PSMB3	PSMA7	psi-mi:“MI:0914”(association)	0.770
PSMB5	POMP	psi-mi:“MI:0915”(physical association)	0.760
PSMB6	POMP	psi-mi:“MI:0915”(physical association)	0.760
POMP	PSMB6	psi-mi:“MI:0915”(physical association)	0.760
POMP	PSMB4	psi-mi:“MI:0915”(physical association)	0.750

BioGRID (157): POMP (Affinity Capture-MS), POMP (Affinity Capture-MS), POMP (Affinity Capture-MS), POMP (Affinity Capture-MS), POMP (Affinity Capture-MS), POMP (Affinity Capture-MS), POMP (Affinity Capture-MS), POMP (Co-fractionation), PSMA4 (Co-fractionation), PSMA5 (Co-fractionation), PSMB7 (Co-fractionation), PSMC2 (Co-fractionation), PSMC3 (Co-fractionation), PSMD2 (Co-fractionation), POMP (Affinity Capture-MS)

ESM2 similar proteins: A0A0G3VTN5, A0A0P0XBU0, A0A2K1L2D9, A2X0Q6, A3A2Z8, A9XMT4, B8YIE8, B9F1C0, C7IW64, F4I096, F4J7T2, F4J7T3, F4JTS8, F4K1J4, O65685, P0C1C7, P0C945, P0CB21, P92973, Q2LAE1, Q53HY2, Q5E9A0, Q5R9L9, Q5Z8V7, Q657D6, Q689G6, Q6IRT3, Q703I1, Q766Z3, Q86XD8, Q8LFU0, Q8S9L0, Q93WK5, Q94FL9, Q94JW8, Q9CAA9, Q9CQT5, Q9FRG8, Q9FZK0, Q9LE42

Diamond homologs: Q0DWQ7, Q3SZV5, Q5R9L9, Q9CQT5, Q9Y244

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 71 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen processing: Ub, ATP-independent proteasomal degradation	16	179.1×	4e-34
Regulation of activated PAK-2p34 by proteasome mediated degradation	19	103.8×	4e-34
Proteasome assembly	25	100.0×	4e-44
Cross-presentation of soluble exogenous antigens (endosomes)	20	99.5×	8e-35
Vpu mediated degradation of CD4	19	98.9×	1e-33
Autodegradation of the E3 ubiquitin ligase COP1	19	98.9×	1e-33
Ubiquitin-dependent degradation of Cyclin D	19	98.9×	1e-33
AUF1 (hnRNP D0) binds and destabilizes mRNA	20	97.4×	8e-35

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	23	21.4×	8e-23

Disease & clinical

Clinical variants and AI predictions

ClinVar

158 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	77
Likely benign	57
Benign	10

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
116	NC_000013.11:g.28659090del	Pathogenic
522801	NM_015932.6(POMP):c.334_335del (p.Ile112fs)	Pathogenic
548959	NM_015932.6(POMP):c.340_344dup (p.Glu115fs)	Pathogenic
548960	NM_015932.6(POMP):c.342_348delinsACC (p.Phe114fs)	Pathogenic
546726	NM_015932.6(POMP):c.326dup (p.Asp109fs)	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

925 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:28668524:G:C	G72R	0.990
13:28668563:G:C	A85P	0.985
13:28668525:G:T	G72V	0.982
13:28668510:T:C	L67P	0.981
13:28668534:C:A	A75D	0.981
13:28664550:T:A	L48H	0.979
13:28668540:T:C	L77P	0.979
13:28668525:G:A	G72D	0.978
13:28664550:T:C	L48P	0.975
13:28668554:G:A	E82K	0.970
13:28672427:T:C	L118P	0.969
13:28668549:A:C	Q80P	0.967
13:28664545:T:A	H46Q	0.966
13:28664545:T:G	H46Q	0.966
13:28668524:G:T	G72C	0.966
13:28672354:T:C	F94L	0.966
13:28672356:T:A	F94L	0.966
13:28672356:T:G	F94L	0.966
13:28672414:T:C	F114L	0.965
13:28672416:T:A	F114L	0.965
13:28672416:T:G	F114L	0.965
13:28672388:T:C	L105S	0.963
13:28678080:A:T	E135V	0.960
13:28668544:A:C	K78N	0.957
13:28668544:A:T	K78N	0.957
13:28672385:T:A	V104D	0.957
13:28672394:G:T	G107V	0.956
13:28664544:A:G	H46R	0.955
13:28668525:G:C	G72A	0.953
13:28668522:A:C	Q71P	0.952

dbSNP variants (sampled 300 via entrez): RS1000043810 (13:28676907 G>A), RS1000417646 (13:28658975 A>C), RS1000640320 (13:28678479 A>G), RS1000821114 (13:28672627 G>A), RS1000896658 (13:28673966 T>G), RS1000994170 (13:28678768 G>A,T), RS1001107754 (13:28672297 T>G), RS1001180573 (13:28662222 A>G), RS1001488698 (13:28671821 A>G), RS1001489626 (13:28659501 G>A,C), RS1001519989 (13:28671520 C>T), RS1001611240 (13:28674717 G>A), RS1001666273 (13:28667874 G>T), RS1001717206 (13:28667705 C>T), RS1001998439 (13:28666843 C>G,T)

Disease associations

OMIM: gene MIM:613386 | disease phenotypes: MIM:601952, MIM:618048

GenCC curated gene-disease

Disease	Classification	Inheritance
keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome	Strong	Autosomal recessive
proteasome-associated autoinflammatory syndrome 2	Strong	Autosomal dominant

Mondo (2): keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome (MONDO:0011169), proteasome-associated autoinflammatory syndrome 2 (MONDO:0054700)

Orphanet (1): Keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome (Orphanet:281201)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C566600	Keratosis Linearis with Ichthyosis Congenita and Sclerosing Keratoderma (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	6
Valproic Acid	affects expression, increases expression	2
Cadmium Chloride	increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
lead acetate	affects cotreatment, decreases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
cupric chloride	increases expression	1
perfluorodecanoic acid	increases expression	1
chloropicrin	increases expression	1
jinfukang	decreases expression	1
Vorinostat	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1
Doxorubicin	increases expression	1
Manganese	increases expression, affects cotreatment, increases abundance	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.